Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.
about
Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based reviewPneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Prevention of Community-Acquired Pneumonia with Available Pneumococcal VaccinesPneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.Phenotypic and molecular study of pneumococci causing respiratory tract infections. A 3-year prospective cohort.A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine.Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.Is there a potential role for protein-conjugate pneumococcal vaccine in older adults?Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.The Clinical Effectiveness of Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy.Theory and strategy for Pneumococcal vaccines in the elderly.Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in SingaporeUpdate in chronic obstructive pulmonary disease 2009.Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults.Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.A Decade of National Heart, Lung, and Blood Institute Programs Supporting COPD Research and Education .Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002-2009.Pneumococcus with the "6E" cps Locus Produces Serotype 6B Capsular Polysaccharide.Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases?Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.Pneumococcal vaccination and chronic respiratory diseases.Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.Cost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany
P2860
Q27007003-7A2A2B6A-DF1E-4D2E-BFB0-FBADB3A4C7FBQ28070059-480F4EEF-69E5-4485-B029-A851A1685A48Q28077703-40347BFA-8205-4004-ABCA-83702A90B582Q30238816-2C0348B8-8218-4F89-BECF-0ECF4343C143Q33706037-9D8E30F8-3AC2-45E1-B6AC-A5E80EF60E1FQ33735215-45F4A1FF-0A44-4055-AF24-CFA5990D8AC9Q33776577-03059FFE-0EAF-40E6-B95E-46E02C30D4CAQ34430844-1A2CBBA0-D939-458F-AAC3-A3EE8EFADA9AQ35782786-7F1FFEDB-5A05-41F5-ABB4-752B98D77486Q36090837-F45B3F67-4DFF-4F84-9AC3-639A2810377DQ36379580-124FB613-1B8D-422C-AFB7-9B0E42A88188Q36523805-052637E6-2E58-4F58-A411-64C9F1974168Q36713715-0B61EA98-5ABD-4D68-A104-95997A63E6AEQ37013129-7C0290CB-7550-4F60-8028-597F10A432E7Q37309215-A9D7A1C3-9E56-42D9-9182-C81D4ED38605Q37384771-218DC6C0-7955-4AAD-AF7B-E7B98087B2CDQ37685565-5B26A99C-D904-4EB7-B2AF-E6A3E415A0F2Q37718404-40B41860-CC39-4C07-B1FA-2A41108FC21DQ37910264-BEA3A068-238F-48E6-AEE0-7D142D792256Q37954709-68A1FBF7-958C-4632-B62E-48BA98CBC8C3Q37981768-C4D13FD3-9DF5-437C-B844-CE5B4BADA880Q38636065-B3E41092-E5B1-4D9B-AF28-838E28D4AF7CQ38992874-E218F98D-4325-4611-990B-055123879E72Q39576336-8643C6C2-CD85-4312-B9B4-1A9CE60C0FB2Q39872559-54EDD1F5-2F3D-4762-A51B-14C1AEFAA340Q44398866-F0E848F4-041C-4F8B-8E6C-C89AEDE6458AQ47162758-41614226-8A19-48C7-A43B-08CAC99EDF9AQ50090256-F1862EC9-15F4-4922-AE89-56A93D53F8A8Q53836109-6B53EF1E-A0FE-4FE5-83BC-9F9BC68574C5Q58286129-23DBE00E-2E44-4E6B-826C-9D6EC4EFB024
P2860
Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Superior immune response to pr ...... obstructive pulmonary disease.
@en
Superior immune response to pr ...... obstructive pulmonary disease.
@nl
type
label
Superior immune response to pr ...... obstructive pulmonary disease.
@en
Superior immune response to pr ...... obstructive pulmonary disease.
@nl
prefLabel
Superior immune response to pr ...... obstructive pulmonary disease.
@en
Superior immune response to pr ...... obstructive pulmonary disease.
@nl
P2093
P2860
P1476
Superior immune response to pr ...... obstructive pulmonary disease
@en
P2093
COPD Clinical Research Network
Fernando J Martinez
George R Washko
Gerard J Criner
John E Connett
Mark T Dransfield
Meilan K Han
Nicholas R Anthonisen
Paul D Scanlon
Prescott G Woodruff
P2860
P304
P356
10.1164/RCCM.200903-0488OC
P407
P50
P577
2009-06-25T00:00:00Z